|
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) |
|
Monte Rosa Therapeutics Inc
GLUE's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Monte Rosa Therapeutics Inc growth rates, revenue grew
in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 60
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 13.29 %
Monte Rosa Therapeutics Inc net loss decreased from $-35 millions, to $-24 millions in III. Quarter 2024,
• More on GLUE's Growth
|
|
Monte Rosa Therapeutics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 6.82 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 30.45.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.06.
• More on GLUE's Valuation
|
|
|
|
|
Monte Rosa Therapeutics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 6.82 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 30.45.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.06.
Monte Rosa Therapeutics Inc Price to Book Ratio is at 2.22 higher than Industry Avg. of -0, and higher than S&P 500 Avg. of 0.01
• More on GLUE's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com